Involvement of the P2X7 purinergic receptor in inflammation: An update of antagonists series since 2009 and their promising therapeutic potential

Current Medicinal Chemistry

Volumn 22, Issue 6, 2015, Pages 713-729

  Baudelet, Davy ^a,b   Lipka, Emmanuelle ^a,c   Millet, Régis ^a,d   Ghinet, Alina ^a,b,e  

^a INSERM   (France)

^b Laboratoire de Pharmacochimie   (France)

^c Laboratoire de Chimie Analytique   (France)

^d Faculté des Sciences Pharmaceutiques et Biologiques Université de Lille   (France)

^e ALEXANDRU IOAN CUZA UNIVERSITY OF IASI   (Romania)

Author keywords

Immune system; Immune related diseases; P2X7R antagonists

Indexed keywords

ADENOSINE TRIPHOSPHATE; INTERLEUKIN 1; PURINERGIC P2X RECEPTOR ANTAGONIST; PURINERGIC P2X7 RECEPTOR; CYTOKINE;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CYTOKINE RELEASE; DEGENERATIVE DISEASE; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOPATHOLOGY; INFLAMMATION; INTRACELLULAR SIGNALING; NONHUMAN; ANIMAL; CHEMISTRY; CLINICAL TRIAL (TOPIC); GENETICS; METABOLISM; PATHOLOGY; SECRETION (PROCESS);

ANIMALS; CLINICAL TRIALS AS TOPIC; CYTOKINES; HUMANS; INFLAMMATION; PURINERGIC P2X RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2X7;

EID: 84923007445     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867322666141212120926     Document Type: Article

References (212)

1. Khakh, B. S.; Burnstock, G. The double life of ATP. Sci. Am., 2009, 301, 84-90.
2. Drury, A. N.; Szent-Györgyi, A. The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart. J. Physiol., 1929, 68, 213-237.
3. Lythgoe, B.; Todd, A. R. Structure and synthesis of nucleotides. Symp. Soc. Exp. Biol., 1947, 1, 15-37.
4. Holton, P. The liberation of adenosine triphosphate on antidromic stimulation of sensory nerves. J. Physiol. (London), 1959, 145, 494-504.
5. Burnstock, G.; Holman, M. E. Spontaneous potential at sympathetic nerve endings in smooth muscle. J. Physiol., 1962, 160, 446-460.
6. Burnstock, G.; Holman, M. E. Effect of denervation and of reserpine treatment on transmission at sympathetic nerve endings. J. Physiol., 1962, 160, 461-469.
7. Burnstock, G. Purinergic nerves. Pharmacol. Rev., 1972, 24, 509-581.
8. Gillespie, J. H. The biological significance of the linkages in adenosine triphosphoric acid. J. Physiol., 1934, 80, 345-358.
9. Burnstock, G. A basis for distinguishing two types of purinergic receptor. In Cell membrane receptors for drugs and hormones: A multidisciplinary approach. Straub, R. W.; Bolis, L. eds.; Raven Press, New York. 1978. pp. 107-118.
10. Brown, C. M.; Burnstock, G. Evidence in support of the P1/P2 purinoceptor hypothesis in the guinea-pig taenia coli. Br. J. Pharmacol., 1981, 73, 617-624.
11. Kennedy, C.; Burnstock, G. Evidence for two types of P2-purinoceptor in longitudinal muscle of the rabbit portal vein. Eur. J. Pharmacol., 1985, 111, 49-56.
12. Webb, T. E.; Simon, J.; Krishek, B. J.; Bateson, A. N.; Smart, T. G.; King, B. F.; Burnstock, G.; Barnard, E. A. Cloning and functional expression of a brain G-protein-coupled ATP receptor. FEBS Lett., 1993, 324, 219-225.
13. Burnstock, G. Discovery of purinergic signalling, the initial resistance and current explosion of interest. Br. J. Pharmacol., 2012, 167, 238-255.
14. Burnstock, G. Purinergic signalling: pathophysiology and therapeutic potential. Keio J. Med., 2013, 62, 63-73.
15. Ralevic, V.; Burnstock, G. Receptors for purines and pyrimidines. Pharmacol. Rev., 1998, 50, 413-492.
16. Palmer, T. M.; Stiles, G. L. Adenosine receptors. Neuropharmacol., 1995, 34, 683-694.
17. North, R. A. Molecular physiology of P2X receptors. Physiol. Rev., 2002, 82, 1013-1067.
18. Valera, S.; Hussy, N.; Evans, R. J.; Adami, N.; North, R. A.; Surprenant, A.; Buell, G. A new class of ligand-gated ion channel defined by P2x receptor for extracellular ATP. Nature, 1994, 371, 516-519.
19. Jiang, L. H.; Baldwin, J. M.; Roger, S.; Baldwin, S. A. Insights into the Molecular Mechanisms Underlying Mammalian P2X7 Receptor Functions and Contributions in Diseases, Revealed by Structural Modeling and Single Nucleotide Polymorphisms. Front. Pharmacol., 2013, 4, 1-55.
20. Di Virgilio, F. The P2Z purinoceptor: An intriguing role in immunity, inflammation and cell death. Immunol. Today, 1995, 16, 524-528.
21. Guile, S. D.; Alcaraz, L.; Birkinshaw, T. N.; Bowers, K. C.; Ebden, M. R.; Furber, M.; Stocks, M. J. Antagonists of the P2X(7) receptor. From lead identification to drug development. J. Med. Chem., 2009, 52, 3123-3141.
22. Ferrari, D.; Pizzirani, C.; Adinolfi, E.; Lemoli, R. M.; Curti, A.; Idzko, M.; Panther, E.; Di Virgilio, F. The P2X7 receptor: A key player in IL-1 processing and release. J. Immunol., 2006, 176, 3877-3883.
23. Stagg, J.; Smyth, M. J. Extracellular adenosine triphosphate and adenosine in cancer. Oncogene, 2010, 29, 5346-5358.
24. Cockcroft, S.; Gomperts, B. D. The ATP4-receptor of rat mast cells. Biochem. J., 1980, 188, 789-798.
25. Surprenant, A.; Rassendren, F.; Kawashima, E.; North, R. A.; Buell, G. The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science, 1996, 272, 735-738.
26. Rassendren, F.; Buell, G. N.; Virginio, C.; Collo, G.; North, R. A.; Surprenant, A. The permeabilizing ATP receptor, P2X7. Cloning and expression of a human cDNA. J. Biol. Chem., 1997, 272, 5482-5486.
27. Alves, L. A.; de Melo R., Ricardo A.; Magalhaes de Souza, C. A.; Santos de Freitas, M.; Nogueira Teixeira, P. C.; Neto Moreira Ferreira, D.; Xavier, R. Fa. The P2X7 receptor: shifting from a low-to a high-conductance channel-an enigmatic phenomenon? Biochim. Biophys. Acta, Biomembranes, 2014, 1838, 2578-2587.
28. Mehta, N.; Kaur, M.; Singh, M.; Chand, S.; Vyas, B.; Silakari, P.; Bahia, M. S.; Silakari, O. Purinergic receptor P2X: A novel target for anti-inflammatory therapy. Bioorg. Med. Chem., 2014, 22, 54-88.
29. Chrovian, C. C.; Rech, J. C.; Bhattacharya, A.; Letavic, M. A. P2X7 antagonists as potential therapeutic agents for the treatment of CNS disorders. Prog. Med. Chem., 2014, 53, 65-100.
30. Burnstock, G. Purinergic signalling in the urinary tract in health and disease. Purinergic Signal., 2014, 10, 103-155.
31. Sugiyama, T. Role of P2X7 receptors in the development of diabetic retinopathy. World J. Diabetes, 2014, 5, 141-145.
32. Bai, H.-Y.; Li, A.-P. P2X(7) receptors in cerebral ischemia. Neurosci. Bull., 2013, 29, 390-398.
33. Nagy, J. Recent Patents on Novel P2X7 Receptor Antagonists Potentially Effective for Treatment of Inflammatory Diseases. Recent Pat. Biomark., 2013, 3, 1-24.
34. Wiley, James S.; Gu, Ben J. A new role for the P2X7 receptor: A scavenger receptor for bacteria and apoptotic cells in the absence of serum and extracellular ATP. Purinergic Signal., 2012, 8, 579-586.
35. Fuller, S. J.; Stokes, L.; Skarratt, K. K.; Gu, B. J.; Wiley, J. S. Genetics of the P2X7 receptor and human disease. Purinergic Signal., 2009, 5, 257-262.
36. Buell, G. N.; Talabot, F.; Gos, A.; Lorenz, J.; Lai, E.; Morris, M. A.; Antonarakis S. E. Gene structure and chromosomal localization of the human P2X7 receptor. Receptors Channels, 1998, 5, 347-354.
37. Burnstock, G.; Kennedy, C. P2X receptors in health and disease. Adv. Pharmacol., 2011, 61, 333-372.
38. Lewis, C.; Neidhart, S.; Holy, C.; North, R. A.; Buell, G.; Surprenant A. Coexpression of P2X2 and P2X3 receptor subunits can account for ATP-gated currents in sensory neurons. Nature, 1995, 10, 432-435.
39. Lê, K. T.; Babinski, K.; Séguéla, P. Central P2X4 and P2X6 Channel Subunits Coassemble into a Novel Heteromeric ATP Receptor. J. Neurosci., 1998, 18, 7152-7159.
40. Guo, C.; Masin, M.; Qureshi, O. S.; Murrell-Lagnado, R. D. Evidence for Functional P2X4/P2X7 Heteromeric Receptors. Mol. Pharmacol., 2007, 72, 1447-1456.
41. Craigie, E.; Birch, R. E.; Unwin, R. J.; Wildman, S. S. The relationship between P2X4 and P2X7: A physiologically important interaction? Front. Physiol., 2013, 4, 1-6.
42. Kawate, T.; Michel, J. C.; Birdsong, W. T.; Gouaux, E. Crystal structure of the ATP-gated P2X(4) ion channel in the closed state. Nature, 2009, 460, 592-598.
43. Hattori, M.; Gouaux, E. Molecular mechanism of ATP binding and ion channel activation in P2X receptors. Nature, 2012, 485, 207-212.
44. Ennion, S.; Evans, R. J. Conserved cysteine residues in the extracellular loop of the human P2X(1) receptor form disulfide bonds and are involved in receptor trafficking to the cell surface. Mol. Pharmacol., 2002, 61, 303-311.
45. Vial, C.; Rigby, R.; Evans, R. J. Contribution of P2X1 receptor intracellular basic residues to channel properties. Biochem. Biophys. Res. Commun., 2006, 350, 244-248.
46. Amstrup, J.; Novak, I. P2X7 receptor activates extracellular signalregulated kinases ERK1 and ERK2 independently of Ca2+ influx. Biochem. J., 2003, 374, 51-61.
47. Khakh, B. S. Molecular physiology of P2X receptors and ATP signalling at synapses. Nat. Rev. Neurosci., 2001, 2, 165-174.
48. Brake, A. J.; Wagenbach, M. J.; Julius, D. New structural motif for ligand-gated ion channels defined by an ionotropic ATP receptor. Nature, 1994, 371, 519-523.
49. North, R. A. Families of ion channels with two hydrophobic segments. Curr. Opin. Cell. Biol., 1996, 8, 474-483.
50. Sun, C.; Heid, M. E.; Keyel, P. A.; Salter, R. S. The second transmembrane domain of P2X7 contributes to dilated pore formation. PLOS ONE, 2013, 8, e61886.
51. Evans, R. J. Structural interpretation of P2X receptor mutagenesis studies on drug action. Br. J. Pharmacol., 2010, 161, 961-971.
52. Nakazawa, K.; Inoue, K.; Ohno, Y. An asparagine residue regulating conductance through P2X2 receptor/channels. Eur. J. Pharmacol., 1998, 347, 141-144.
53. Evans, R. J. Orthosteric and allosteric binding sites of P2X receptors. Eur. Biophys. J., 2009, 38, 319-327.
54. North, R. A.; Jarvis, M. F. P2X receptors as drug targets. Mol. Pharmacol., 2013, 83, 759-769.
55. Bean, B. P. ATP-activated channels in rat and bullfrog sensory neurons: concentration dependence and kinetics. J. Neurosci., 1990, 10, 1-10.
56. Jiang, L. H.; Kim, M.; Spelta, V.; Bo, X.; Surprenant, A.; North, R. A. Subunit arrangement in P2X receptors. J. Neurosci., 2003, 23, 8903-8910.
57. Vial, C.; Roberts, J. A.; Evans, R. J. Molecular properties of ATPgated P2X receptor ion channels. Trends Pharmacol. Sci., 2004, 25, 487-493.
58. Clyne, J. D.; Wang, L. F.; Hume, R. I. Mutational analysis of the conserved cysteines of the rat P2X2 purinoceptor. J. Neurosci., 2002, 22, 3873-3880.
59. Acuna-Castillo, C.; Coddou, C.; Bull, P.; Brito, J.; Huidobro-Toro, J. P. Differential role of extracellular histidines in copper, zinc, magnesium and proton modulation of the P2X7 purinergic receptor. J. Neurochem., 2007, 101, 17-26.
60. Lenertz, L. Y.; Wang, Z.; Guadarrama, A.; Hill, L. M.; Gavala, M. L.; Bertics, P. J. Mutation of putative N-linked glycosylation sites on the human nucleotide receptor P2X7 reveals a key residue important for receptor function. Biochemistry, 2010, 49, 4611-4619.
61. Denlinger, L. C.; Fisette, P. L.; Sommer, J. A.; Watters, J. J.; Prabhu, U.; Dubyak, G. R.; Proctor, R. A.; Bertics, P. J. Cutting edge: The nucleotide receptor P2X7 contains multiple protein-and lipid-interaction motifs including a potential binding site for bacterial lipopolysaccharide. J. Immunol., 2001, 167, 1871-1876.
62. Roger, S.; Pelegrin, P.; Surprenant, A. Facilitation of P2X7 receptor currents and membrane blebbing via constitutive and dynamic calmodulin binding. J. Neurosci., 2008, 28, 6393-6401.
63. Denlinger, L. C.; Sommer, J. A.; Parker, K.; Gudipaty, L.; Fisette, P. L.; Watters, J. W.; Proctor, R. A.; Dubyak, G. R.; Bertics, P. J. Mutation of a dibasic amino acid motif within the C terminus of the P2X7 nucleotide receptor results in trafficking defects and impaired function. J. Immunol., 2003, 171, 1304-1311.
64. Smart, M. L.; Gu, B.; Panchal, R. G.; Wiley, J.; Cromer, B.; Williams, D. A.; Petrou, S. P2X7 receptor cell surface expression and cytolytic pore formation are regulated by a distal C-terminal region. J. Biol. Chem., 2003, 278, 8853-8860.
65. Becker, D.; Woltersdorf, R.; Boldt, W.; Schmitz, S.; Braam, U.; Schmalzing, G.; Markwardt, F. The P2X7 carboxyl tail is a regulatory module of P2X7 receptor channel activity. J. Biol. Chem., 2008, 283, 25725-25734.
66. Kim, M.; Jiang, L. H.; Wilson, H. L.; North, R. A.; Surprenant, A. Proteomic and functional evidence for a P2X7 receptor signalling complex. EMBO J., 2001, 20, 6347-6358.
67. Arulkumaran, N.; Unwin, R. J.; Tam, F. W. K. A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases. Expert. Opin. Investig. Drugs, 2011, 20, 897-915.
68. Schwarz, N.; Drouot, L.; Nicke, A.; Fliegert, R.; Boyer, O.; Guse, A. H.; Haag, F.; Adriouch, S.; Koch-Nolte, F. Alternative splicing of the N-terminal cytosolic and transmembrane domains of P2X7 controls gating of the ion channel by ADP-ribosylation. PLOS ONE, 2012, 7, e41269.
69. North, R. A.; Verkhratsky, A. Purinergic transmission in the central nervous system. Pflugers Arch., 2006, 452, 479-485.
70. Deaglio, S.; Dwyer, K. M.; Gao, W.; Friedman, D.; Usheva, A.; Erat, A.; Chen, J. F.; Enjyoji, K.; Linden, J.; Oukka, M.; Kuchroo, V. K.; Strom, T. B.; Robson, S. C. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med., 2007, 204, 1257-1265.
71. Bours, M. J.; Swennen, E. L.; Di Virgilio, F.; Cronstein, B. N.; Dagnelie, P. C. Adenosine 5'-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol. Ther., 2006, 112, 358-404.
72. Dubyak, G. R. P2X7 receptor regulation of non-classical secretion from immune effector cells. Cell. Microbiol., 2012, 14, 1697-1706.
73. D'Hondt, C.; Ponsaerts, R.; De Smedt, H.; Vinken, M.; De Vuyst, E.; De Bock, M.; Wang, N.; Rogiers, V.; Leybaert, L.; Himpens, B.; Bultynck, G. Pannexin channels in ATP release and beyond: An unexpected rendezvous at the endoplasmic reticulum. Cell. Signal., 2011, 23, 305-316.
74. Coco, S.; Calegari, F.; Pravettoni, E.; Pozzi, D.; Taverna, E.; Rosa, P.; Matteoli, M.; Verderio, C. Storage and release of ATP from astrocytes in culture. J. Biol. Chem., 2003, 278, 1354-1362.
75. Imura, Y.; Morizawa, Y.; Komatsu, R.; Shibata, K.; Shinozaki, Y.; Kasai, H.; Moriishi, K.; Moriyama, Y.; Koizumi, S. Microglia release ATP by exocytosis. GLIA, 2013, 61, 1320-1330.
76. Gorini, S.; Gatta, L.; Pontecorvo, L.; Vitiello, L.; Ia Sala, A. Regulation of innate immunity by extracellular nucleotides. Am. J. Blood Res., 2013, 3, 14-28.
77. Baroja-Mazo, A.; Barberà-Cremades, M.; Pelegrin, P. The participation of plasma membrane hemichannels to purinergic signaling. Biochim. Biophys. Acta, 2013, 1828, 79-93.
78. Gu, B.; Bendall, L. J.; Wiley, J. S. Adenosine triphosphate-induced shedding of CD23 and L-selectin (CD62L) from lymphocytes is mediated by the same receptor but different metalloproteases. Blood, 1998, 92, 946-951.
79. Gu, B. J.; Wiley, J. S. Rapid ATP-induced release of matrix metalloproteinase 9 is mediated by the P2X7 receptor. Blood, 2006, 107, 4946-4953.
80. Andrei, C.; Margiocco, P.; Poggi, A.; Lotti, L. V.; Torrisi, M. R.; Rubartelli, A. Phospholipases C and A2 control lysosome-mediated IL-1 beta secretion: Implications for inflammatory processes. Proc. Natl. Acad. Sci. USA., 2004, 101, 9745-9750.
81. McKenzie, A.; Wilson, H. L.; Kiss-Toth, E.; Dower, S. K.; North, R. A.; Surprenant, A. Rapid secretion of interleukin-1beta by microvesicle shedding. Immunity, 2001, 15, 825-835.
82. Costa-Junior, H. M.; Sarmento Vieira, F.; Coutinho-Silva, R. C terminus of the P2X7 receptor: Treasure hunting. Purinergic Signal., 2011, 7, 7-19.
83. Gan, B. S.; Krump, E.; Shrode, L. D.; Grinstein, S. Loading pyranine via purinergic receptors or hypotonic stress for measurement of cytosolic pH by imaging. Am. J. Physiol., 1998, 275, C1158-C1166.
84. Virginio, C.; Mckenzie, A.; North, R. A.; Surprenant, A. Kinetics of cell lysis, dye uptake and permeability changes in cells expressing the rat P2X7 receptor. J. Physiol., 1999, 519, 335-346
85. Bianco, F.; Pravettoni, E.; Colombo, A.; Schenk, U.; Moeller, T.; Matteoli, M.; Verderio, C. Astrocyte-derived ATP induces vesicle shedding and IL-1 beta release from microglia. J. Immunol., 2005, 174, 7268-7277.
86. Gulinelli, S.; Salaro, E.; Vuerich, M.; Bozzato, D.; Pizzirani, C.; Bolognesi, G.; Idzko, M.; Di Virgilio, F.; Ferrari, D. IL-18 associates to microvesicles shed from human macrophages by a LPS/TLR-4 independent mechanism in response to P2X receptor stimulation. Eur. J. Immunol., 2012, 42, 3334-3345.
87. Verderio, C; Muzio, L; Turola, E; Bergami, A; Novellino, L; Ruffini, F; Riganti, L; Corradini, I; Francolini, M; Garzetti, L; Maiorino, C.; Servida, F.; Vercelli, A.; Rocca, M.; Dalla Libera, D.; Martinelli, V.; Comi, G.; Martino, G.; Matteoli, M.; Furlan, R Myeloid microvesicles are a marker and therapeutic target for neuroinflammation. Ann. Neurol., 2012, 72, 610-624.
88. Antonucci, F.; Turola, E.; Riganti, L.; Caleo, M.; Gabrielli, M.; Perrotta, C.; Novellino, L.; Clementi, E.; Giussani, P.; Viani, P.; Matteoli, M.; Verderio, C. Microvesicles released from microglia stimulate synaptic activity via enhanced sphingolipid metabolism. EMBO J., 2012, 31, 1231-1240.
89. Agosta, F.; Dalla Libera, D.; Spinelli, E. G.; Finardi, A.; Canu, E.; Bergami, A.; Bocchio Chiavetto, L.; Baronio, M.; Comi, G.; Martino, G.; Matteoli, M.; Magnani, G.; Verderio, C.; Furlan, R. Myeloid microvesicles in cerebrospinal fluid are associated with myelin damage and neuronal loss in mild cognitive impairment and Alzheimer disease. Ann. Neurol., 2014, 76, 813-825.
90. Lister, M. F.; Sharkey, J.; Sawatzky, D. A.; Hodgkiss, J. P.; Davidson, D. J.; Rossi, A. G.; Finlayson, K. The role of the purinergic P2X7 receptor in inflammation. J. Inflamm., 2007, 4, 5.
91. Perl, A.; Gergely, P. Jr.; Puskas, F.; Banki, K. Metabolic switches of T-cell activation and apoptosis. Antioxid. Redox Signal., 2002, 4, 427-443.
92. Lemaire, I.; Falzoni, S.; Leduc, N.; Zhang, B.; Pellegatti, P.; Adinolfi, E.; Chiozzi, P.; Di Virgilio, F. Involvement of the purinergic P2X7 receptor in the formation of multinucleated giant cells. J. Immunol., 2006, 177, 7257-7265.
93. Ferrari, D.; Pizzirani, C.; Gulinelli, S.; Callegari, G.; Chiozzi, P.; Idzko, M.; Panther, E.; Di Virgilio, F. Modulation of P2X7 receptor functions by polymyxin B: crucial role of the hydrophobic tail of the antibiotic molecule. Br. J. Pharmacol., 2007, 150, 445-454.
94. Volonté, C.; Apolloni, S.; Skaper, S. D.; Burnstock, G. P2X7 receptors: channels, pores and more. CNS Neurol. Disord. Drug. Targets, 2012, 11, 705-721.
95. Yan, Z; Li, S; Liang, Z; Tomic, M.; Stojilkovic, S. S. The P2X7 receptor channel pore dilates under physiological ion conditions. J. Gen. Physiol., 2008, 132, 563-573.
96. Khadra, A.; Tomic, Melanija; Y., Zonghe; Z., H.; Sherman, A.; Stojilkovic, S. S. Dual gating mechanism and function of P2X7 receptor channels. Biophys. J., 2013, 104, 2612-2621.
97. Yan, Z.; Khadra, A.; Li, S.; Tomic, M.; Sherman, A.; Stojilkovic, St. S. Experimental characterization and mathematical modeling of P2X7 receptor channel gating. J. Neurosci., 2010, 30, 14213-14224.
98. Steinberg, T. H.; Silverstein, S. C. Extracellular ATP4-promotes cation fluxes in the J774 mouse macrophage cell line. J. Biol. Chem., 1987, 262, 3118-3122.
99. Baricordi, O. R.; Melchiorri, L.; Adinolfi, E.; Falzoni, S.; Chiozzi, P.; Buell, G.; Di Virgilio, F. Increased proliferation rate of lymphoid cells transfected with the P2X(7) ATP receptor. J. Biol. Chem., 1999, 274, 33206-33208.
100. Bianco, F.; Ceruti, S; Colombo, A; Fumagalli, M.; Ferrari, D.; Pizzirani, C.; Matteoli, M.; Di Virgilio, F.; Abbracchio, M. P.; Verderio, C. A role for P2X7 in microglial proliferation. J. Neurochem., 2006, 99, 745-758.
101. Jantaratnotai, N.; Choi, H. B.; McLarnon, J. G. ATP stimulates chemokine production via a store-operated calcium entry pathway in C6 glioma cells. BMC Cancer, 2009, 9, 442.
102. Pelegrin, P.; Surprenant, A. Pannexin-1 mediates large pore formation and interleukin-1beta release by the ATP-gated P2X7 receptor. EMBO J., 2006, 25, 5071-5082.
103. Gunosewoyo, H.; Coster, M. J.; Kassiou, M. Molecular probes for P2X7 receptor studies. Curr. Med. Chem., 2007, 14, 1505-1523.
104. Tatham, P. E.; Lindau, M. ATP-induced pore formation in the plasma membrane of rat peritoneal mast cells. J. Gen. Physiol., 1990, 95, 459-476.
105. Zemkova, H.; Balik, A.; Jindrichová, M.; Vávra, V. Molecular structure of purinergic P2X receptors and their expression in the hypothalamus and pituitary. Physiol. Res., 2008, 57, S23-S38.
106. Pelegrin, P. Many ways to dilate the P2X7 receptor pore. Br. J. Pharmacol., 2011, 163, 908-911.
107. Niemi, K.; Teirilae, L.; Lappalainen, J.; Rajamaeki, K.; Baumann, M. H.; Oeoerni, K.; Wolff, H.; Kovanen, P. T.; Matikainen, S.; Eklund, K. K. Serum amyloid A activates the NLRP3 inflammasome via P2X7 receptor and a cathepsin B-sensitive pathway. J. Immunol., 2011, 186, 6119-6128.
108. Elssner, A.; Duncan, M.; Gavrilin, M.; Wewers, M. D. A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1 beta processing and release. J. Immunol., 2004, 172, 4987-4994.
109. Leiva-Salcedo, E.; Coddou, C.; Rodriguez, F. E.; Penna, A.; Lopez, X.; Neira, T.; Fernandez, R.; Imarai, M.; Rios, M.; Escobar, J.; Montoya, M.; Huidobro-Toro, J. P.; Escobar, A.; Acuña-Castillo, C. Lipopolysaccharide inhibits the channel activity of the P2X7 receptor. Mediators Inflamm., 2011, 152625, 1-12.
110. Cabrini, G.; Falzoni, S.; Forchap, S. L.; Pellegatti, P.; Balboni, A.; Agostini, P.; Cuneo, A.; Castoldi, G.; Baricordi, O. R.; Di Virgilio, F. A His-155 to Tyr polymorphism confers gain-of-function to the human P2X7 receptor of human leukemic lymphocytes. J. Immunol., 2005, 175, 82-89.
111. Ohlendorff, S. D.; Tofteng, C. L.; Jensen, J. E.; Petersen, S.; Civitelli, R.; Fenger, M.; Abrahamsen, B.; Hermann, A. P.; Eiken, P.; Jørgensen, N. R. Single nucleotide polymorphisms in the P2X7 gene are associated to fracture risk and to effect of estrogen treatment. Pharmacogenet. Genomics, 2007, 17, 555-567.
112. Shemon, A. N.; Sluyter, R.; Fernando, S. L.; Clarke, A. L.; Dao-Ung, L. P.; Skarratt, K. K.; Saunders, B. M.; Tan, K. S.; Gu, B. J.; Fuller, S. J.; Britton, W. J.; Petrou, S.; Wiley, J. S. A Thr357 to Ser polymorphism in homozygous and compound heterozygous subjects causes absent or reduced P2X7 function and impairs ATPinduced mycobacterial killing by macrophages. J. Biol. Chem., 2006, 281, 2079-2086.
113. Cheewatrakoolpong, B.; Gilchrest, H.; Anthes, J. C.; Greenfeder, S. Identification and characterization of splice variants of the human P2X7 ATP channel. Biochem. Biophys. Res. Commun., 2005, 332, 17-27.
114. Feng, Y. H.; Li, X.; Wang, L.; Zhou, L.; Gorodeski, G. I. A truncated P2X7 receptor variant (P2X7-j) endogenously expressed in cervical cancer cells antagonizes the full-length P2X7 receptor through hetero-oligomerization. J. Biol. Chem., 2006, 281, 17228-17237.
115. Nicke, A.; Kuan, Y. H.; Masin, M.; Rettinger, J.; Marquez-Klaka, B.; Bender, O.; Górecki, D. C.; Murrell-Lagnado, R. D.; Soto, F. A functional P2X7 splice variant with an alternative transmembrane domain 1 escapes gene inactivation in P2X7 knock-out mice. J. Biol. Chem., 2009, 284, 25813-25822.
116. Burnstock, G.; Knight, G. E. Cellular distribution and functions of P2 receptor subtypes in different systems. Int. Rev. Cytol., 2004, 240, 31-304.
117. Garcia-Marcos, M; Perez-Andres, E; Tandel, S; Fontanils, U; Kumps, A; Kabre, E; Gomez-Munoz, A; Marino, A; Dehaye, J.-P.; Pochet, S. Coupling of two pools of P2X7 receptors to distinct intracellular signaling pathways in rat submandibular gland. J. Lipid Res., 2006, 47, 705-714.
118. Dinarello, C. A. The IL-1 family and inflammatory diseases. Clin. Exp. Rheumatol., 2002, 20, S1-S13.
119. Bevilacqua, M. P.; Stengelin, S.; Gimbrone, M. A. Jr. Seed B. Endothelial leukocyte adhesion molecule 1: An inducible receptor for neutrophils related to complement regulatory proteins and lectins. Science, 1989, 243, 1160-1165.
120. Perregaux, D.; Gabel, C. A. Interleukin-1 beta maturation and release in response to ATP and nigericin. Evidence that potassium depletion mediated by these agents is a necessary and common feature of their activity. J. Biol. Chem., 1994, 269, 15195-15203.
121. Alves, L. A.; Bezerra, R. J. S.; Faria, R. X.; Ferreira, L. G. B.; Frutuoso, V. S. Physiological roles and potential therapeutic applications of the P2X7 receptor in inflammation and pain. Molecules, 2013, 18, 10953-10972.
122. Dinarello, C. A. Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol., 2009, 27, 519-550.
123. Parvathenani, L. K.; Tertyshnikova, S.; Greco, C. R.; Roberts, S. B.; Robertson, B.; Posmantur, R. P2X7 mediates superoxide production in primary microglia and is up-regulated in a transgenic mouse model of Alzheimer's disease. J. Biol. Chem., 2003, 278, 13309-13317.
124. Ghayur, T.; Banerjee, S.; Hugunin, M.; Bulter, D.; Herzog, L.; Carter, A.; Quintal, L.; Sekut, L.; Talanian, R.; Paskind, M.; Wong, W.; Kamen, R.; Tracey, D.; Allen, H. Caspase-1 processes IFNgamma-inducing factor and regulates LPS-induced IFN-gamma production. Nature, 1997, 386, 619-623.
125. Gu, Y.; Kuida, K.; Tsutsui, H.; Ku, G.; Hsiao, K.; Fleming, M. A.; Hayashi, N.; Higashino, K.; Okamura, H.; Nakanishi, K.; Kurimoto, M.; Tanimoto, T.; Flavell, R. A.; Sato, V.; Harding, M. W.; Livingston, D. J.; Su, M. S. Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme. Science, 1997, 275, 206-209.
126. Dinarello, C. A. The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1. N. Engl. J. Med., 2000, 343, 732-734.
127. Goldblatt, F.; Isenberg, D. A. New therapies for rheumatoid arthritis. Clin. Exp. Immunol., 2005, 140, 195-204.
128. Moynagh, P. N. The interleukin-1 signalling pathway in astrocytes: A key contributor to inflammation in the brain. J. Anat., 2005, 207, 265-269.
129. Shore, S. A.; Moore, P. E. Effects of cytokines on contractile and dilator responses of airway smooth muscle. Clin. Exp. Pharmacol. Physiol., 2002, 29, 859-866.
130. Braddock, M.; Quinn, A. Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention. Nat. Rev. Drug Discov., 2004, 3, 330-339.
131. Gwee, K. A.; Collins, S. M.; Read, N. W.; Rajnakova, A.; Deng, Y.; Graham, J. C.; McKendrick, M. W.; Moochhala, S. M. Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome. Gut, 2003, 52, 523-526.
132. Keating, C.; Pelegrin, P.; Martinez, C. M.; Grundy, D. P2X7 receptor-dependent intestinal afferent hypersensitivity in a mouse model of postinfectious irritable bowel syndrome. J. Immunol., 2011, 187, 1467-1474.
133. Nicklin, M. J. H.; Hughes, D. E.; Barton, J. L.; Ure, J. M.; Duff, G. W. Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene. J. Exp. Med., 2000, 191, 303-312.
134. Horai, R.; Saijo, S.; Tanioka, H.; Nakae, S.; Sudo, K.; Okahara, A.; Ikuse, T.; Asano, M.; Iwakura, Y. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J. Exp. Med., 2000, 191, 313-320.
135. Walker, D. G.; Kim, S. U.; McGeer, P. L. Complement and cytokine gene expression in cultured microglial derived from postmortem human brains. J. Neurosci. Res., 1995, 40, 478-493.
136. Thornberry, N. A.; Bull, H. G.; Calaycay, J. R.; Chapman, K. T.; Howard, A. D.; Kostura, M. J.; Miller, D. K.; Molineaux, S. M.; Weidner, J. R.; Aunins, J.; Elliston, K. O.; Ayala, J. M.; Casano, F. J.; Chin, J.; Ding, G. J. F.; Egger, L. A.; Gaffney, E. P.; Limjuco, G.; Palyha, O. C.; Raju, S. M.; Rolando, A. M.; Salley, J. P.; Yamin, T. T.; Lee, T. D.; Shively, J. E.; Maccross, M.; Mumford, R. A.; Schmidt, J. A.; Tocci, M. J. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature, 1992, 356, 768-774.
137. Gauer, S.; Sichler, O.; Obermuller, N.; Holzmann, Y.; Kiss, E.; Sobkowiak, E.; Pfeilschifter, J.; Geiger, H.; Mühl, H.; Hauser, I. A. IL-18 is expressed in the intercalated cell of human kidney. Kidney Int., 2007, 72, 1081-1087.
138. Dinarello, C. A. Unraveling the NALP-3/IL-1beta inflammasome: A big lesson from a small mutation. Immunity, 2004, 20, 243-244.
139. Gallucci, S.; Matzinger, P. Danger signals: SOS to the immune system. Curr. Opin. Immunol., 2001, 13, 114-119.
140. Ia Sala, A.; Ferrari, D.; Di Virgilio, F.; Idzko, M.; Norgauer, J.; Girolomoni, G. Alerting and tuning the immune response by extracellular nucleotides. J. Leukoc. Biol., 2003, 73, 339-343.
141. Roberts, J. A.; Lukewich, M. K.; Sharkey, K. A.; Furness, J. B.; Mawe, G. M.; Lomax, A. E. The roles of purinergic signaling during gastrointestinal inflammation. Curr. Opin. Pharmacol., 2012, 12, 659-666.
142. Friedman, D. J.; Kunzli, B. M.; YI, A. R.; Sevigny, J.; Berberat, P. O.; Enjyoji, K.; Csizmadia, E.; Friess, H.; Robson, S. C. From the Cover: CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase susceptibility to inflammatory bowel disease. Proc. Natl. Acad. Sci. USA, 2009, 106, 16788-16793.
143. Cesaro, A.; Brest, P.; Hofman, V.; Hébuterne, X.; Wildman, S.; Ferrua, B.; Marchetti, S.; Doglio, A.; Vouret-Craviari, V.; Galland, F.; Naquet, P.; Mograbi, B.; Unwin, R.; Hofman, P. Amplification loop of the inflammatory process is induced by P2X7R activation in intestinal epithelial cells in response to neutrophil transepithelial migration. Am. J. Physiol. Gastrointest. Liver Physiol., 2010, 299, G32-G42.
144. Sanz, J. M.; Di Virgilio, F. Kinetics and mechanism of ATPdependent IL-1 beta release from microglial cells. J. Immunol., 2000, 164, 4893-4898.
145. Solle, M.; Labasi, J.; Perregaux, D. G.; Stam, E.; Petrushova, N.; Koller, B. H.; Griffiths, R. J.; Gabel, C. A. Altered cytokine production in mice lacking P2X(7) receptors. J. Biol. Chem., 2001, 276, 125-132.
146. Labasi, J. M.; Petrushova, N.; Donovan, C.; McCurdy, S.; Lira, P.; Payette, M. M.; Brissette, W.; Wicks, J. R.; Audoly, L.; Gabel, C. A. Absence of the P2X7 receptor alters leukocyte function and attenuates an inflammatory response. J. Immunol., 2002, 168, 6436-6445.
147. Ferrari, D.; Villalba, M.; Chiozzi, P.; Falzoni, S.; Ricciardi-Castagnoli, P.; Di Virgilio, F. Mouse microglial cells express a plasma membrane pore gated by extracellular ATP. J. Immunol., 1996, 156, 1531-1539.
148. Ferrari, D.; Chiozzi, P.; Falzoni, S.; Hanau, S.; Di Virgilio, F. Purinergic modulation of interleukin-1 beta release from microglial cells stimulated with bacterial endotoxin. J. Exp. Med., 1997, 185, 579-582.
149. Brough, D.; Le Feuvre, R. A.; Iwakura, Y.; Rothwell, N. J. Purinergic (P2X7) receptor activation of microglia induces cell death via an interleukin-1-independent mechanism. Mol. Cell. Neurosci., 2002, 19, 272-280.
150. Lawson, L. J.; Perry, V. H.; Dri, P.; Gordon, S. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience, 1990, 3, 151-170.
151. Mogi, M.; Harada, M.; Narabayashi, H.; Inagaki, H.; Minami, M.; Nagatsu, T. Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neuroscience Lett., 1996, 211, 13-16.
152. Marcellino, D.; Suarez-Boomgaard, D.; Sanchez-Reina, M. D. On the role of P2X(7) receptors in dopamine nerve cell degeneration in a rat model of Parkinson's disease: studies with the P2X(7) receptor antagonist A-438079. J. Neural Transm., 2010, 117, 681-687.
153. Tran, C. N.; Lundy, S. K.; Fox, D. A. Synovial biology and T cells in rheumatoid arthritis. Pathophysiology, 2005, 12, 183-189.
154. Ryan, L. M.; Rachow, J. W.; McCarty, D. J. Synovial fluid ATP: A potential substrate for the production of inorganic pyrophosphate. J. Rheumatol., 1991, 18, 716-720.
155. Solini, A.; Chiozzi, P.; Morelli, A.; Fellin, R.; Di Virgilio, F. Human primary fibroblasts in vitro express a purinergic P2X7 receptor coupled to ion fluxes, microvesicle formation and IL-6 release. J. Cell. Sci., 1999, 112, 297-305.
156. Gourine, A. V.; Poputnikov, D. M.; Zhernosek, N.; Melenchuk, E. V.; Gerstberger, R.; Spyer, K. M.; Gourine, V. N. P2 receptor blockade attenuates fever and cytokine responses induced by lipopolysaccharide in rats. Br. J. Pharmacol., 2005, 146, 139-145.
157. Dell'Antonio, G.; Quattrini, A.; Cin, E. D.; Fulgenzi, A.; Ferrero, M. E. Relief of inflammatory pain in rats by local use of the selective P2X7 ATP receptor inhibitor, oxidized ATP. Arthritis Rheum., 2002, 46, 3378-3385.
158. Feldmann, M.; Brennan, F. M.; Maini, R. N. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol., 1996, 14, 397-440
159. Jo, S. K.; Cha, D. R.; Cho, W. Y.; Kim, H. K.; Chang, K. H.; Yun, S. Y.; Won, N. H. Inflammatory cytokines and lipopolysaccharide induce Fas-mediated apoptosis in renal tubular cells. Nephron., 2002, 91, 406-415.
160. Shum, P.; Gross, A.; Ma, L.; McGarry, D. G.; Gregory, H.; Rampe, D.; Ringheim, G.; Sabol, J. S.; Francis, A. WO 2005014555, 2005.
161. Mariathasan, S.; Weiss, D. S.; Newton, K.; McBride, J.; O'Rourke, K.; Roose-Girma, M.; Lee, W. P.; Weinrauch, Y.; Monack, D. M.; Dixit, V. M. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature, 2006, 440, 228-232.
162. Pfeiffer, Z. A.; Aga, M.; Prabhu, U.; Watters, J. J.; Hall, D. J.; Bertics, P. J. The nucleotide receptor P2X7 mediates actin reorganization and membrane blebbing in RAW 264.7 macrophages via p38 MAP kinase and Rho. J. Leukoc. Biol., 2004, 75, 1173-1182.
163. Allam, R.; Darisipudi, M. N.; Rupanagudi, K. V.; Lichtnekert, J.; Tschopp, J.; Anders, H. J. Cutting edge: cyclic polypeptide and aminoglycoside antibiotics trigger IL-1 secretion by activating the NLRP3 inflammasome. J. Immunol., 2011, 186, 2714-2718.
164. Ferrari, D.; Chiozzi, P.; Falzoni, S.; Dal Susino, M.; Melchiorri, L.; Baricordi, O. R.; Di Virgilio, F. Extracellular ATP triggers IL-1 beta release by activating the purinergic P2Z receptor of human macrophages. J. Immunol., 1997, 159, 1451-1458.
165. Sluyter, R.; Shemon, A. N.; Wiley, J. S. Glu496 to Ala polymorphism in the P2X7 receptor impairs ATP-induced IL-1 beta release from human monocytes. J. Immunol., 2004, 172, 3399-3405.
166. Jelassi, B.; Anchelin, M.; Chamouton, J.; Cayuela, M. L.; Clarysse, L.; Li, J.; Gore, J.; Jiang, L. H.; Roger, S. Anthraquinone emodin inhibits human cancer cell invasiveness by antagonizing P2X7 receptors. Carcinogenesis, 2013, 34, 1487-1496.
167. Pearce, J. M. Edmé Félix Alfred Vulpian (1826-1887). J. Neurol., 2002, 249, 1749-1750.
168. Marx, J. Cancer research. Inflammation and cancer: The link grows stronger. Science, 2004, 306, 966-968.
169. El Omar, E. M.; Carrington, M.; Chow, W. H.; McColl, K. E. L.; Bream, J. H.; Young, H. A.; Herrera, J.; Lissowska, J.; Yuan, C. C.; Rothman, N.; Lanyon, G.; Martin, M.; Fraumeni, J. F.; Rabkin C. S. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature, 2000, 404, 398-402.
170. El Omar, E. M.; Carrington, M.; Chow, W. H.; McColl, K. E. L.; Bream, J. H.; Young, H. A.; Herrera, J.; Lissowska, J.; Yuan, C. C.; Rothman, N.; Lanyon, G.; Martin, M.; Fraumeni, J. F.; Rabkin, C. S. The role of interleukin-1 polymorphisms in the pathogenesis of gastric cancer. Nature, 2001, 412, 99.
171. Adinolfi, E.; Melchiorri, L.; Falzoni, S.; Chiozzi, P.; Morelli, A.; Tieghi, A.; Cuneo, A.; Castoldi, G.; Di Virgilio, F.; Baricordi, O. R. P2X7 receptor expression in evolutive and indolent forms of chronic B lymphocytic leukemia. Blood, 2002, 99, 706-708.
172. Slater, M.; Danieletto, S.; Pooley, M.; The, L. C.; Gidley-Baird, A.; Barden, J. A. Differentiation between cancerous and normal hyperplastic lobules in breast lesions. Breast Cancer Res. Treat., 2004, 83, 1-10.
173. Li, X.; Zhou, L.; Feng, Y. H.; Abdul-Karim, F. W.; Gorodeski, G. I. The P2X7 receptor: A novel biomarker of uterine epithelial cancers. Cancer Epidemiol. Biomarkers Prev., 2006, 15, 1906-1913.
174. Baricordi, O. R.; Ferrari, D.; Melchiorri, L.; Chiozzi, P.; Hanau, S.; Chiari, E.; Rubini, M.; Di Virgilio, F. An ATP-activated channel is involved in mitogenic stimulation of human T lymphocytes. Blood, 1996, 87, 682-690.
175. Ryu, J. K.; Jantaratnotai, N.; Serrano-Perez, M. C.; McGeer, P. L.; McLarnon, J. G. Block of purinergic P2X7R inhibits tumor growth in a C6 glioma brain tumor animal model. J. Neuropathol. Exp. Neurol., 2011, 70, 13-22.
176. Candelario, K. M.; Steindler, D. A. The role of extracellular vesicles in the progression of neurodegenerative disease and cancer. Trends Mol. Med., 2014, 20, 368-374.
177. Vader, P.; Breakefield, X. O.; Wood, M. J. A. Extracellular vesicles: emerging targets for cancer therapy. Trends Mol. Med., 2014, 20, 385-393.
178. D'Asti, E.; Garnier, D.; Lee, T. H.; Montermini, L.; Meehan, B.; Rak, J. Oncogenic extracellular vesicles in brain tumor progression. Front. Physiol., 2012, 3, 294, 1-15.
179. Aguirre, A.; Shoji, K. F.; Saez, J. C.; Henriquez, M.; Quest, A. F. G. FasL-triggered death of Jurkat cells requires caspase 8-induced, ATP-dependent cross-talk between Fas and the purinergic receptor P2X(7). J. Cell. Physiol., 2013, 228, 485-493.
180. Shoji, K. F.; Saez, P. J.; Harcha, P. A.; Aguila, H. L.; Saez, J. C. Pannexin1 channels act downstream of P2X 7 receptors in ATPinduced murine T-cell death. Channels, 2014, 8, 142-156.
181. Adinolfi, E.; Callegari, M. G.; Ferrari, D.; Bolognesi, C.; Minelli, M.; Wieckowski, M. R.; Pinton, P.; Rizzuto, R.; Di Virgilio, F. Correction to Fig. (5) published in "Functional Role of Syndecan-1 Cytoplasmic V Region in Lamellipodial Spreading, Actin Bundling, and Cell Migration" (Mol. Biol. Cell [2005] 16, 3678-3691). Mol. Biol. Cell., 2005, 16, 5053-5054.
182. Jelassi, B.; Chantôme, A.; Alcaraz-Pérez, F.; Baroja-Mazo, A.; Cayuela, M. L.; Pelegrin, P.; Surprenant, A.; Roger, S. P2X(7) receptor activation enhances SK3 channels-and cystein cathepsindependent cancer cells invasiveness. Oncogene, 2011, 30, 2108-2122.
183. Burnstock, G. Purinergic signalling. Br. J. Pharmacol., 2006, 147, S172-S181.
184. Wang, W.; Xiao, J. B.; Adachi, M.; Liu, Z.; Zhou, J. 4-aminopyridine induces apoptosis of human acute myeloid leukemia cells via increasing [Ca2+]i through P2X7 receptor pathway. Cell. Physiol. Biochem., 2011, 28, 199-208.
185. Ghiringhelli, F.; Apetoh, L.; Tesniere, A.; Aymeric, L.; Ma, Y.; Ortiz, C.; Vermaelen, K.; Panaretakis, T.; Mignot, G.; Ullrich, E.; Perfettini, J.-L.; Schlemmer, F.; Tasdemir, E.; Uhl, M.; Genin, P.; Civas, A.; Ryffel, B.; Kanellopoulos, J.; Tschopp, J.; Andre, F.; Lidereau, R.; McLaughlin, N. M.; Haynes, N. M.; Smyth, M. J.; Kroemer, G.; Zitvogel, L. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat. Med., 2009, 15, 1170-1178.
186. Friedle, S. A.; Curet, M. A.; Watters, J. J. Recent patents on novel P2X(7) receptor antagonists and their potential for reducing central nervous system inflammation. Recent Pat. CNS Drug Discov., 2010, 5, 35-45.
187. Wang, X.; Arcuino, G.; Takano, T.; Lin, J.; Peng, W. G.; Wan, P.; Li, P.; Xu, Q.; Liu, Q. S.; Goldman, S. A.; Nedergaard, M. P2X7 receptor inhibition improves recovery after spinal cord injury. Nat. Med., 2004, 10, 821-827.
188. Baxter, A.; Brough, S.; McInally, T.; Mortimore, M.; Cladingboel, D. WO 9929660, 1999.
189. Baxter, A.; McInally, T.; Mortimore, M.; Cladingboel, D. WO 9929661, 1999.
190. Baxter, A.; Cheshire, D.; McInally, T.; Mortimore, M.; Cladingboel, D. WO 9929686, 1999.
191. Tokumitsu, H.; Chijiwa, T.; Hagiwara, M.; Mizutani, A.; Terasawa, M.; Hidaka, H. KN-62, 1-[N,O-bis(5-isoquinolinesulfonyl)-Nmethyl-L-tyrosyl]-4-phenylpiperazine, a specific inhibitor of Ca2+/calmodulin-dependent protein kinase II. J. Biol. Chem., 1990, 265, 4315-4320.
192. Gunosewoyo, H.; Coster, M. J.; Bennett, M. R.; Kassiou, M. Purinergic P2X(7) receptor antagonists: Chemistry and fundamentals of biological screening. Bioorg. Med. Chem., 2009, 17, 4861-4865.
193. Hopper, A. T.; Campbell, B. M.; Kao, H.; Pintchovski, S. A.; Staal, R. G. W. Chapter Four-Recent Developments in Targeting Neuroinflammation in Disease. Annu. Rep. Med. Chem., 2012, 47, 37-53.
194. Keystone, E. C.; Wang, M. M.; Layton, M.; Hollis, S.; McInnes, I. B.; D1520C00001 Study Team. Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine. Ann. Rheum. Dis., 2012, 71, 1630-1635.
195. Duplantier, A. J.; Dombroski, M. A.; Subramanyam, C.; Beaulieu, A. M.; Chang, S. P.; Gabel, C. A.; Jordan, C.; Kalgutkar, A. S.; Kraus, K. G.; Labasi, J. M.; Mussari, C.; Perregaux, D. G.; Shepard, R.; Taylor, T. J.; Trevena, K. A.; Whitney-Pickett, C.; Yoon, K. Optimization of the physicochemical and pharmacokinetic attributes in a 6-azauracil series of P2X7 receptor antagonists leading to the discovery of the clinical candidate CE-224,535. Bioorg. Med. Chem. Lett., 2011, 21, 3708-3711.
196. [Evotec P2X7 Antagonist Program][http://www.evotec.com/article/en/Press-releases/Evotec-grants-exclusive-rights-on-EVT-401-in-China-to-Conba-Pharmaceutical/2274 (accessed Dec 2, 2013)]
197. Chambers, L. J.; Gleave, R.; Senger, S.; Walter, D. S. WO 2008003697, 2008.
198. Beswick, P. J.; Chambers, L. J.; Davies, D. J.; Dean, D.; Demont, E. H.; Roomans, S.; Walter, D. S. WO 2007141267, 2007.
199. Beswick, P. J.; Walter, D. S. WO 2007141269, 2007.
200. Chambers, L. J.; Stevens, J. A.; Moses, A. P.; Michel, A. D.; Walter, D. S.; Davies, D. J.; Livermore, D. G.; Fonfria, E.; Demont, E. H.; Vimal, M.; Theobald, P. J.; Beswick, P. J.; Gleave, R. J.; Roman, S. A.; Senger, S. Synthesis and structure-activity relationships of a series of (1H-pyrazol-4-yl)acetamide antagonists of the P2X7 receptor. Bioorg. Med. Chem. Lett., 2010, 20, 3161-3164.
201. Gleave, R. J.; Walter, D. S.; Beswick, P. J.; Fonfria, E.; Michel, A. D.; Roman, S. A.; Tang, S. P. Synthesis and biological activity of a series of tetrasubstituted-imidazoles as P2X(7) antagonists. Bioorg. Med. Chem. Lett., 2010, 20, 4951-4954.
202. Beswick, P. J.; Billinton, A.; Chambers, L. J.; Dean, D. K.; Fonfria, E.; Gleave, R. J.; Medhurst, S. J.; Michel, A. D.; Moses, A. P.; Patel, S.; Roman, S. A.; Roomans, S.; Senger, S.; Stevens, J. A.; Walter, D. S. Structure-activity relationships and in vivo activity of (1H-pyrazol-4-yl)acetamide antagonists of the P2X(7) receptor. Bioorg. Med. Chem. Lett., 2010, 20, 4653-4656.
203. Abdi, M. H.; Beswick, P. J.; Billinton, A.; Chambers, L. J.; Charlton, A.; Collins, S. D.; Collis, K. L.; Dean, D. K.; Fonfria, E.; Gleave, R. J.; Lejeune, C. L.; Livermore, D. G.; Medhurst, S. J.; Michel, A. D.; Moses, A. P.; Page, L.; Patel, S.; Roman, S. A.; Senger, S.; Slingsby, B.; Steadman, J. G. A.; Stevens, A. J.; Walter, D. S. Discovery and structure-activity relationships of a series of pyroglutamic acid amide antagonists of the P2X7 receptor. Bioorg. Med. Chem. Lett., 2010, 20, 5080-5084.
204. Abberley, L.; Bebius, A.; Beswick, P. J.; Billinton, A.; Collis, K. L.; Dean, D. K.; Fonfria, E.; Gleave, R. J.; Medhurst, S. J.; Michel, A. D.; Moses, A. P.; Patel, S.; Roman, S. A.; Scoccitti, T.; Smith, B.; Steadman, J. G. A.; Walter, D. S. Identification of 2-oxo-N-(phenylmethyl)-4-imidazolidinecarboxamide antagonists of the P2X(7) receptor. Bioorg. Med. Chem. Lett., 2010, 20, 6370-6374.
205. Ali, Z.; Laurijssens, B.; Ostenfeld, T.; McHugh, S.; Stylianou, A.; Scott-Stevens, P.; Hosking, L.; Dewit, O.; Richardson, J. C.; Chen, C. Pharmacokinetic and pharmacodynamic profiling of a P2X7 receptor allosteric modulator GSK1482160 in healthy human subjects. Br. J. Clin. Pharmacol., 2013, 75, 197-207.
206. Murphy, N.; Cowley, T. R.; Richardson, J. C.; Virley, D.; Upton, N.; Walter, D.; Lynch, M. A. The neuroprotective effect of a specific P2X receptor antagonist derives from its ability to inhibit assembly of the NLRP3 inflammasome in glial cells. Brain Pathol., 2012, 22, 295-306.
207. Baudelet, D.; Schifano-Faux, N.; Ghinet, A.; Dezitter, X.; Barbotin, F.; Gautret, P.; Rigo, B.; Chavatte, P.; Millet, R.; Furman, C.; Vaccher, C.; Lipka, E. Enantioseparation of pyroglutamide derivatives on polysaccharide based chiral stationary phases by highperformance liquid chromatography and supercritical fluid chromatography: A comparative study. J. Chroma. A, 2014, 1363, 257-269.
208. Baudelet, D.; Ghinet, A.; Furman, C.; Dezitter, X.; Gautret, P.; Rigo, B.; Millet, R.; Vaccher, C.; Lipka, E. Antagonists of the P2X7 receptor: mechanism of enantioselective recognition using highly sulfated and sulfobutylether cyclodextrins by capillary electrokinetic chromatography. Electrophoresis, 2014, 35, 2892-2899.
209. Lee, W. G.; Lee, S. D.; Cho, J. H.; Jung, Y.; Kim, J. H.; Hien, T. T.; Kang, K. W.; Ko, H.; Kim, Y. C. Structure-activity relationships and optimization of 3,5-dichloropyridine derivatives as novel P2X(7) receptor antagonists. J. Med. Chem., 2012, 55, 3687-3698.
210. Letavic, M. A.; Lord, B.; Bischoff, F.; Hawryluk, N. A.; Pieters, S.; Rech, J. C.; Sales, Z.; Velter, A. I.; Ao, H.; Bonaventure, P.; Contreras, V.; Jiang, X.; Morton, K. L.; Scott, B.; Wang, Q.; Wickenden, A. D.; Carruthers, N. I.; Bhattacharya, A. Synthesis and Pharmacological Characterization of Two Novel, Brain Penetrating P2X7 Antagonists. ACS Med. Chem. Lett., 2013, 4, 419-422.
211. Bhattacharya, A.; Wang, Q.; Ao, H.; Shoblock, J. R.; Lord, B.; Aluisio, L.; Fraser, I.; Nepomuceno, D.; Neff, R. A.; Welty, N.; Lovenberg, T. W.; Bonaventure, P.; Wickenden, A. D.; Letavic, M. A. Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567. Br. J. Pharmacol., 2013, 170, 624-640.
212. Donnelly-Roberts, D. L.; Namovic, M. T.; Surber, B.; Vaidyanathan, S. X.; Perez-Medrano, A.; Wang, Y.; Carroll, W. A.; Jarvis, M. F. [3H]A-804598 ([3H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a novel, potent, and selective antagonist radioligand for P2X7 receptors. Neuropharmacology, 2008, 56, 223-229.